India cautions drugmakers against advertising prescription weight-loss medicines

India’s drug regulator has cautioned pharmaceutical companies against directly or indirectly promoting prescription medicines meant for weight management, amid rising concerns over aggressive marketing of obesity drugs.

In an advisory issued this week, the authorities reminded drugmakers that prescription medicines cannot be advertised to the public under existing regulations. Companies were also warned against using awareness campaigns on obesity as a means to indirectly promote specific drugs.

Officials said some promotional material and digital campaigns were creating the impression that medication alone can address obesity. The regulator emphasised that such messaging may mislead patients and encourage self-medication without proper medical consultation.

The advisory comes at a time when global pharmaceutical companies are expanding their presence in the obesity treatment market, with new drugs attracting attention for their potential to aid weight loss. However, regulators said marketing practices must remain within the legal framework governing prescription medicines.

Public health experts have also underlined that obesity management requires sustained lifestyle changes including balanced nutrition, physical activity and medical supervision where necessary.

The regulator said it will closely monitor promotional activities and warned that violations of advertising norms could invite regulatory action under the Drugs and Magic Remedies Act and other applicable provisions.